Evaluation of the Efficacy of Sole Endovascular Treatment for Intracranial Tumors

Patients aged 18 years or older

Patients with suspected meningioma showing a tendency to increase in size on MRI

No exclusion based on history of cancer

Patients who have provided written informed consent based on their own free will after receiving a full explanation and fully understanding the study. In cases where the patient is unable to provide valid consent due to conditions such as aphasia, written consent must be obtained from a legally authorized representative.

Patients eligible for percutaneous endovascular surgery under local anesthesia or intravenous sedation

Patients with tumor lesions showing significant midline shift or brain edema requiring craniotomy for tumor resection

Patients with tumor lesions fed predominantly by prominent intradural arteries

Patients diagnosed with Neurofibromatosis type II

Patients diagnosed with tumor lesions in the cranial bone (including intraosseous meningioma)

Patients with a Karnofsky Performance Status (KPS) score of 70 or lower, or a modified Rankin Scale (mRS) score of 4 or higher.

Patients judged to be unable to safely undergo examination due to severe aphasia or higher brain dysfunction

Patients with bleeding tendencies, coagulation disorders, or severe renal dysfunction (eGFR <30 mL/min/1.73 m2)

Patients with an allergy to contrast media

Patients with a history of hypersensitivity to iodine

Patients with severe thyroid disease

Patients with hypersensitivity to cyanoacrylate, formaldehyde, or dyes (D&C Violet No. 2)

Pregnant or breastfeeding patients

Any other patients judged by the principal investigator or sub-investigators to be inappropriate as study subjects